Inhibition of green tea polyphenol EGCG((−)-epigallocatechin-3-gallate) on the proliferation of gastric cancer cells by suppressing canonical wnt/β-catenin signalling pathway

Abstract

(-)-Epigallocatechin-3-gallate (EGCG), the major polyphenol in green tea, could affect carcinogenesis and development of many cancers. However, the effects and underlying mechanisms of EGCG on gastric cancer remain unclear. We found that EGCG significantly inhibited proliferation and increased apoptosis of SGC-7901 cells in vitro. The decreased expressions of p-β-catenin(Ser552), p-GSK3β(S9) and β-catenin target genes were detected in SGC-7901 cells after treated by EGCG. XAV939 and β-catenin plasmid were further used to demonstrate the inhibition of EGCG on canonical Wnt/β-catenin signalling. Moreover, EGCG significantly inhibited gastric tumour growth in vivo by inhibiting Wnt/β-catenin signalling. Taken together, our findings establish that EGCG suppressed gastric cancer cell proliferation and demonstrate that this inhibitory effect is related to canonical Wnt/β-catenin signalling. This study raises a new insight into gastric cancer prevention and therapy, and provides evidence that green tea could be used as a nutraceutical beverage.

Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine

“…EGCG can inhibit cell proliferation through multiple ways in many types of cancer cells. It inhibits cell proliferation in human bladder cancer SW-780, breast cancer MDA-MB-231 and NSCLC A549 cells, and inhibits tumor growth in gastric cancer SGC-7901 xenograft mice [89,94,95]. It also induces apoptosis in human oral cancer KB, head and neck cancer FaDu, NSCLC A549, and breast cancer MCF-7 cells [96,97].…”

“…EGCG possesses various biological effects including anti-obesity and anti-hyperuricemia, anti-oxidative, anti-viral, anti-bacterial, anti-infective, anti-angiogenic, anti-inflammatory and anti-cancer activities [80][81][82][83][84]. It is reported to present anti-cancer effects in variety of cancer cells, including lung, colorectal, prostate, stomach, liver, cervical, breast, leukemia, gastric, bladder cancers [85][86][87][88][89][90]. Among its anti-cancer activities, EGCG exhibits multiple pharmacological actions, including the suppression of cell growth, proliferation, metastasis and angiogenesis, induction of apoptosis, and enhancement of anti-cancer immunity [85,86,[91][92][93][94].…”

Epigallocatechin-3-gallate suppresses cell proliferation and promotes apoptosis in Ec9706 and Eca109 esophageal carcinoma cells

“…In the present study, EGCG was demonstrated to suppress the viability of esophageal cancer Eca109 and Ec9706 cells via inducing apoptosis in an EGCG dose-dependent manner. EGCG has been reported to induce cancer cell apoptosis through different pathways involving the pro-oxidant, epigenetic modulation of apoptosis-related genes, including human telomerase reverse transcriptase, and to reduce cell proliferation through the modulation of cell cycle progression (25)(26)(27).…”

Epigallocatechin‐3‐gallate inhibits proliferation and induces apoptosis in odontogenic keratocyst keratinocytes

“…VEGF) and apoptosis (e.g. P53 , BAX , BCL2 , caspase 3; Sur & Panda, ; Yang, Du, & Yang, ). To the best of our knowledge, no direct evidence has shown that EGCG modulates WNT/JNK pathway in tumour cells.…”